Keywords
prostate-specific antigen
urinary infections
How to Cite
Abstract
Urinary tract infections secondary to benign prostatic hyperplasia occur because the prostate enlargement causes an obstruction of the urethra that leads to urine retention in the bladder. Objective: To associate the determination of prostate-specific antigen with the diagnosis of benign prostatic hyperplasia in men with symptoms of urinary tract infections in repeated occasions despite being treated with antibiotics. Methods: We analyzed 134 medical records of men aged 40 to 60 years old who presented symptoms of urinary tract infections in more than one occasion despite being under antibiotic treatment, attended at the Centro de Salud Dispensario Juan Pablo II, Oruro, Bolivia. Results: We found that 64.2% of the patients presented benign prostatic hyperplasia and that, among them, 75.6% showed prostate-specific antigen levels higher than 4 ng/mL. A statistically significant association was found between benign prostatic hyperplasia and prostate-specific antigen levels higher than 4 ng/mL (p < 0.05). The proportion of patients with symptoms of recurrent urinary tract infections despite being under antibiotic treatment who presented benign prostatic hyperplasia was higher than 0.5 (p < 0.05). Conclusion: The determination of prostate-specific antigen in men aged 40 to 60 years old who present symptoms of urinary tract infections in more than one occasion despite being under antibiotic treatment is useful to establish whether they present or not an underlying benign prostatic hyperplasia.
References
1. Catalona WJ. History of the discovery and clinical translation of prostate-specific antigen. Asian J Urol 2014; 1:12-4. https://doi.org/10.1016/j.ajur.2014.09.008
2. Sistema de Prueba Antígeno Prostático Específico Total (tPSA) Código de Producto: 2125-300 [Internet]. Com.ec. [Consultado 2023 dic 2]. Disponible en:https://reactlab.com.ec/wp-content/uploads/2024/01/PSA-AccuBind-ELISA-2125-300-Rev.3-Spanish.pdf
3. El análisis inmunoenzimométrico para micropozo. PLDC de C de APEL en el SHM. Antígeno Prostático Específico Libre (APEl) Código de Producto: 2325-30000 [Internet]. Com.ec. [Consultado 2023 dic 2]. Disponible en: https://reactlab.com.ec/wp-content/uploads/2024/01/FPSA-ELISA-AccuBind-2325300.pdf
4. McNally CJ, Ruddock MW, Moore T, McKenna DJ. Biomarkers That Differentiate Benign Prostatic Hyperplasia from Prostate Cancer: A Literature Review. Cancer Manag Res 2020; 12: 5225-41. https://doi.org/10.2147/cmar.s250829
5. Lokeshwar SD, Harper BT, Webb E, Jordan A, Dykes TA, Neal DE Jr et al. Epidemiology and treatment modalities for the management of benign prostatic hyperplasia. Transl Androl Urol 2019; 8: 529-39. https://doi.org/10.21037/tau.2019.10.01
6. GBD 2019 Benign Prostatic Hyperplasia Collaborators. The global, regional, and national burden of benign prostatic hyperplasia in 204 countries and territories from 2000 to 2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Healthy Longev 2022; 3: E754-76.
7. Lee CL, Kuo HC. Pathophysiology of benign prostate enlargement and lower urinary tract symptoms: Current concepts. Tzu Chi Med J 2017; 29: 79-83. https://doi.org/10.4103/tcmj.tcmj_20_17
8. Devlin C, Simms M, Maitland N. Benign prostatic hyperplasia – what do we know? BJU Int 2021; 127: 389–99. https://doi.org/10.1111/bju.15229
9. Calogero AE, Burgio G, Condorelli RA, Cannarella R, La Vignera S. Epidemiology and risk factors of lower urinary tract symptoms/benign prostatic hyperplasia and erectile dysfunction. Aging Male 2019; 22: 12-19. https://doi.org/10.1080/13685538.2018.1434772
10. Kaikai L, Guorong Y, Yangyang W, Xinze X, Xiaowei H, Aibo P, Dong H, Qing Y, Tao S. The causal effect of metabolic syndrome and its components on benign prostatic hyperplasia: A univariable and multivariable Mendelian randomization study. Prostate 2023; 83: 1358–64. https://doi.org/10.1002/pros.24598
11. Barboza Hernández M. Hiperplasia prostática benigna. Revista Médica Sinergia 2017; 2:11–6. https://doi.org/10.31434/rms.v2i8.91
12. Cardona-Arias J, Ramírez Roldán C, Álvarez Tamayo S, Mena-Paz D, Higuita Gutiérrez L. Prevalencia de uropatógenos en los pacientes atendidos en un hospital del departamento de Antioquia-Colombia. Archivos de Medicina 2014; 10: 1-14.
13. Klein RD, Hultgren SJ. Urinary tract infections: microbial pathogenesis, host-pathogen interactions and new treatment strategies. Nat Rev Microbiol 2020; 18: 211-26. https://doi.org/10.1038/s41579-020-0324-0
14. Molina R, X. Filella X, Ballesta A. El antígeno prostático específico en el diagnóstico precoz del cáncer de próstata. Medicina Integral 2000; 36: 199-202.
15. Lim KB. Epidemiology of clinical benign prostatic hyperplasia. Asian J Urol 2017; 4: 148-51. https://doi.org/10.1016/j.ajur.2017.06.004
16. Steers WD, Zorn B. Benign prostatic hyperplasia. Dis Mon 1995; 41: 437-97. https://doi.org/10.1016/s0011-5029(95)90022-5
17. Egan KB. The Epidemiology of Benign Prostatic Hyperplasia Associated with Lower Urinary Tract Symptoms: Prevalence and Incident Rates. Urol Clin North Am 2016; 43: 289-97. https://doi.org/10.1016/j.ucl.2016.04.001
18. Castiñeiras Fernández J, Cozar Olmo J, Fernández-Pro A, Martín J, Brenes Bermúdez F, Naval Pulido E, Molero J, Pérez Morales D. Criterios de derivación en hiperplasia benigna de próstata para atención primaria. Actas Urol Esp 2010; 34: 24-34. https://doi.org/10.1016/S0210-4806(10)70007-3
19. Prestigiacomo AF, Lilja H, Pettersson K, Wolfert RL, Stamey TA. A comparison of the free fraction of serum prostate specific antigen in men with benign and cancerous prostates: the best-case scenario. J Urol 1996; 156 (2 Pt 1): 350-54. https://doi.org/10.1097/00005392-199608000-00004
20. Catalona WJ, Smith DS, Wolfert RL, Wang TJ, Rittenhouse HG, Ratliff TL, Nadler RB. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA 1995; 274: 1214-20. PMID: 7563511
21. Wolff JM, Boeckmann W, Effert PJ, Habib FK, Jakse G. Increased discrimination between benign prostatic hyperplasia and prostate cancer through measurement of percentage free PSA. Anticancer Res 1997; 17(4B): 2993-94. PMID: 9329583
22. León G, León E. Specific prostatic antigen (PSA) and its relationship to benign prostatic hypertrophy (BPH) in elderly adults. Recinto Pijullo. Canton Urdaneta. 2015 [Internet]. Edu.ec. [Consultado 2024 Mar 31]. Disponible en: https://sga.unemi.edu.ec/media/evidenciasiv/2018/02/15/articulo_2018215111232.pdf.
23. Bushman W. Etiology, epidemiology, and natural history of benign prostatic hyperplasia. Urol Clin North Am 2009; 36: 403-15. https://doi.org/10.1016/j.ucl.2009.07.003